Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT06440811 · COMPLETED

Trial details

NCT number: NCT06440811
Sponsor: Xijing Hospital
Status: COMPLETED
Study type: OBSERVATIONAL

Immune-related Adverse Event Chemotherapeutic Toxicity Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2021-01-01
Primary completion: 2022-06-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.